Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor ...Middle East

PR Newswire - News

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor )

Apple Storegoogle play

Also on site :